Adding brentuximab vedotin to lenalidomide and rituximab improves OS in R/R DLBCL
Category: B-cell lymphoma
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
CD19-targeted chimeric antigen receptor (CAR) T cells have provided a breakthrough in the treatment of patients with relapsed and/or refractory lar…
Subgrouping germinal center-derived B-cell lymphomas based on machine learning-deduced DNA methylation modules
To the Editor: Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the most common lymphomas, both exhibiting features of germinal center-derived B-cells (gcBCs).…
Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors
A large body of evidence suggests that hypoxia drives aggressive molecular features of malignant cells irrespective of cancer type. Non-Hodgkin lym…
Patterns of incident Burkitt lymphoma during the HIV epidemic among the Black African and White population in South Africa
Burkitt lymphoma (BL) may be HIV-associated but data on BL trends in South Africa (SA), where HIV is highly prevalent, are scarce. We compared BL i…
Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma
CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy has recently been approved as second-line treatment for relapsed/refractory large B-…
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
Older patients with lymphoma are typically underrepresented in clinical trials with chimeric antigen receptor T cell (CAR T) therapy. In this multi…
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diag…